<span item_type="fundamental" item_id="aefed53a7a4c2a7642f530c1d6f4d248" counter_id="ST/US/ANTX" env="prod"></span><span item_type="announcement" item_id="582075918896599681" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.31, missing the estimate of USD -0.22.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -10.73 M.</p><p></p><h3>Research and Development (R&amp;D) Expenses</h3><p>R&amp;D expenses for the third quarter of 2025 were $7.0 million, compared to $8.3 million for the same period during 2024, primarily due to decreased clinical trial expenses and personnel-related expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-ex99_1.htm"></span></p><h3>General and Administrative (G&amp;A) Expenses</h3><p>G&amp;A expenses for the third quarter of 2025 were $3.0 million, compared to $3.5 million for the same period during 2024, due to decreased personnel-related expenses and professional services expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-ex99_1.htm"></span></p><h3>Restructuring Charges</h3><p>There were no restructuring charges in the third quarter of 2025, whereas restructuring charges for the third quarter of 2024 were $2.2 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-ex99_1.htm"></span></p><h3>Interest Income</h3><p>Interest income for the third quarter of 2025 was $0.7 million, compared to $1.3 million for the same period in 2024, due to lower cash, cash equivalents, and investment balances.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-ex99_1.htm"></span></p><h3>Net Loss</h3><p>Net loss for the third quarter of 2025 was $9.4 million, compared to $12.7 million for the same period during 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-ex99_1.htm"></span></p><h3>Cash Position</h3><p>The company had cash, cash equivalents, and investments of $65.1 million at September 30, 2025, and projects that existing cash will sustain operations into 2028 under the current operating plan.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-ex99_1.htm"></span></p><h3>Outlook / Guidance</h3><p>AN2 Therapeutics anticipates Phase 1 data for AN2-502998 in the first quarter of 2026 and plans to initiate a Phase 2 proof-of-concept study in 2026, depending on the Phase 1 study’s outcome. The company expects to advance its first oncology compound into development in early 2026 and its second oncology compound in mid-2026. Discussions are underway with the U.S. government to fund Phase 2 development of epetraborole in acute melioidosis.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1880438/000119312525277662/antx-ex99_1.htm"></span></p>

AN2 Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0